Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00058396 | Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00059995 | MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 |
| clinicaltrials |
| NCT00061880 | BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | — | BioCryst PharmaceuticalsINDUSTRY | 1 | May 30, 2013 | clinicaltrials |
| NCT00262743 | Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 73 | Mayo ClinicOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00659568 | Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma | completed | Phase 1 | 28 | London Health Sciences CentreOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00593944 | Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)(MDX1342-02) | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00849654 | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma(PCYC-04753) | completed | Phase 1 | 66 | Pharmacyclics LLC.INDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00006009 | Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma | completed | Phase 1 | — | Stanford UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00022048 | Bevacizumab in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | — | Stanford UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00070421 | Study of @neWorld: A Virtual Community for Children With Cancer | completed | Phase 1 / Phase 2 | — | Leap of Faith TechnologiesINDUSTRY | 1 | May 15, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00093639 | Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | completed | Phase 1 / Phase 2 | — | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00003425 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | completed | Phase 1 / Phase 2 | 25 | University of KentuckyOTHER | 1 | Apr 26, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT00698243 | Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 128 | Astellas Pharma IncINDUSTRY | 3 | Apr 15, 2013 | clinicaltrials |
| NCT00004162 | Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma | completed | Phase 1 | 48 | University of Alabama at BirminghamOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00008697 | Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00066326 | Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 1 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00003956 | Combination Chemotherapy in Treating Patients With Advanced Cancer | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00038051 | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00278330 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00003406 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer | completed | Phase 1 / Phase 2 | 30 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT01130662 | Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of KansasOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00003368 | Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00379574 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | completed | Phase 1 / Phase 2 | 49 | Asan Medical CenterOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00651781 | Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00215605 | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | completed | Phase 1 | 85 | ExelixisINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00002750 | Melphalan in Patients With Neoplastic Meningitis | completed | Phase 1 | 6 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00823524 | Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00002980 | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer | completed | Phase 1 | — | California Cancer ConsortiumNETWORK | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00268229 | Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 21 | The Cleveland ClinicOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00544284 | Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00962507 | Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | completed | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00002625 | Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00002862 | Perillyl Alcohol in Treating Patients With Refractory Cancer | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2013source: clinicaltrials